[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Article Processing Charge Confirmation

marta.spasic@mdpi.com <marta.spasic@mdpi.com>
atas nama
Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Sel 06/12/2022 17.46

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Dear Dr. Yuliani,

Thank you very much for submitting your manuscript to Pharmaceutics:

Journal name: Pharmaceutics
Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Stability and Compatibility Approach for Quality Assessment of Pharmaceutical Compounding for Pediatric Patients
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945

We confirm that, if accepted for publication, the following Article Processing Charges (APC), 2400 CHF, will apply to your article:

Journal APC: 2400 CHF
Total APC: 2400 CHF

Please confirm that the APC is correct at the below link:
https://susy.mdpi.com/user/manuscripts/apc_info/f556c3b2fd38fcb291a9e88e9e45bdd9

Please note that our invoice amount is fixed in Swiss Francs (CHF). If you need to pay in another currency, please note that the exchange rate of the invoice is fixed only when the editor confirms the invoice amount to the billing department.

Please also check and confirm that the below information for the invoice address is correct:

Name: Sri Hartati Yuliani
Address: Sri Hartati Yuliani
Universitas Sanata Dharma
Kampus III Universitas Sanata Dharma Paingan Maguwohardjo Depok Sleman
Yogyakarta Indonesia
55282 Sleman
Indonesia
E-Mail: srihartatiyuliani@usd.ac.id

You may be entitled to a discount if you have previously received a discount code. Please note that reviewer vouchers must be applied before acceptance for publication. Vouchers cannot be applied once an APC invoice has been issued. IOAP discounts can be combined with other available discounts (e.g., reviewer vouchers, discounts offered by the Editorial Office); Please note that only one discount through an IOAP scheme is permitted per paper. If you need to add any discount or replace the current discount with another type of discount, please contact the Pharmaceutics Editorial Office as soon as possible.

Please confirm that you support open access publishing, which allows unlimited access to your published paper and that you will pay the Article Processing Charge if your manuscript is accepted.

Thank you in advance for your cooperation. I look forward to hearing from you.

Kind regards,
Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma
LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:
https://www.mdpi.com/about/announcements/4307

Awards Open for Application:
https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 7455 363

Re: [Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Major Revisions

Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Sel 20/12/2022 21.23

Kepada: marta.spasic@mdpi.com <marta.spasic@mdpi.com>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Dear Marta,

Thank you very much for your email. Unfortunately, we are out of office due to the Christmas and new year holiday. Is it still possible for us to submit our revised version after 15 January 2023?
We are looking forward for your response.

Regards,
Dr. Sri Hartati Yuliani

Get Outlook for Android

From: marta.spasic@mdpi.com <marta.spasic@mdpi.com> on behalf of Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Sent: Tuesday, December 20, 2022 9:02:00 PM
To: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>
Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>; Dita Maria Virginia <virginia@usd.ac.id>; Michael Raharja Gani <mr_gani@usd.ac.id>; Dika Octa <dikaocta@usd.ac.id>; Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Subject: [Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Major Revisions

Dear Dr. Yuliani,

Thank you again for your manuscript submission:

Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Stability and Compatibility Approach for Quality Assessment of Pharmaceutical Compounding for Pediatric Patients
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945

Your manuscript has now been reviewed by experts in the field. Please find your manuscript with the referee reports at this link:

https://susy.mdpi.com/user/manuscripts/resubmit/f556c3b2fd38fcb291a9e88e9e45bdd9

Please revise the manuscript according to the referees' comments and upload the revised file within 10 days.

Please use the version of your manuscript found at the above link for your revisions.

(I) Please check that all references are relevant to the contents of the manuscript.
(II) Any revisions to the manuscript should be marked up using the "Track Changes" function if you are using MS Word/LaTeX, such that any changes can be easily viewed by the editors and reviewers.
(III) Please provide a cover letter to explain, point by point, the details of the revisions to the manuscript and your responses to the referees' comments.
(IV) If you found it impossible to address certain comments in the review reports, please include an explanation in your appeal.
(V) The revised version will be sent to the editors and reviewers.

If one of the referees has suggested that your manuscript should undergo extensive English revisions, please address this issue during revision. We propose that you use one of the editing services listed at https://www.mdpi.com/authors/english or have your manuscript checked by a native English-speaking colleague.

Do not hesitate to contact us if you have any questions regarding the revision of your manuscript. We look forward to hearing from you soon.

Kind regards,
Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma
LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:
https://www.mdpi.com/about/announcements/4307

Awards Open for Application:
https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 7455 363

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Response to Academic Editor Comments Required

Marta Spasic <marta.spasic@mdpi.com>

Kam 24/11/2022 19.16

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>

1 lampiran (45 KB)

pharmaceutics-1940862 - Academic Editor Comments.pdf;

Dear authors,

I hope this email finds you well. Thank you for resubmitting your manuscript to Pharmaceutics.

I am contacting you regarding some issues that have to be resolved before we continue processing the manuscript. According to our journal policy, when resubmitting the manuscript the point-to-point response to both reviewers and Academic Editor have to be provided. Since the Academic Editor who provided the final decision for the previously submitted manuscript has made some comments about the issues that should be addressed, please provide us with a response. I am sending the comments you received with final decision in the attachment for your convenience.

Additionally, I would like to confirm with you that you agree with the "Open Review" for this manuscript, since it differs from the option you had chosen for previous submission.

Please forward the responses at your earliest convenience so we could continue processing the manuscript. If you have any questions, do not hesitate to contact me.

Kind regards,

Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma
LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:

https://www.mdpi.com/about/announcements/4307

Awards Open for Application:
https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 7455 363

Re: [Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Response to Academic Editor Comments Required

Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Jum 25/11/2022 22.58

Kepada: Marta Spasic <marta.spasic@mdpi.com>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>

1 lampiran (14 KB)

Response to Academic Editor Decision.docx;

Dear Marta,

Thank you for your notification regarding our submission. Herewith, we would like to send our response to the Academic Editor.
We also confirm that we choose the "Close review" similar to our previous submission.
We hope this version of the manuscript can be considered in the next stage of edtiorial process.
Thank you very much.

Regards,
Dr. Sri Hartati Yuliani

From: Marta Spasic <marta.spasic@mdpi.com>
Sent: Thursday, November 24, 2022 7:16 PM
To: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>
Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>; Dita Maria Virginia <virginia@usd.ac.id>; Michael Raharja Gani <mr_gani@usd.ac.id>; Dika Octa <dikaocta@usd.ac.id>
Subject: [Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Response to Academic Editor Comments Required

Dear authors,

I hope this email finds you well. Thank you for resubmitting your manuscript to Pharmaceutics.

I am contacting you regarding some issues that have to be resolved before we continue processing the manuscript. According to our journal policy, when resubmitting the manuscript the point-to-point response to both reviewers and Academic Editor have to be provided. Since the Academic Editor who provided the final decision for the previously submitted manuscript has made some comments about the issues that should be addressed, please provide us with a response. I am sending the comments you received with final decision in the attachment for your convenience.

Additionally, I would like to confirm with you that you agree with the "Open Review" for this manuscript, since it differs from the option you

had chosen for previous submission.

Please forward the responses at your earliest convenience so we could continue processing the manuscript. If you have any questions, do not hesitate to contact me.

Kind regards,

Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma
LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:
https://www.mdpi.com/about/announcements/4307

Awards Open for Application:
https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 7455 363

User Menu

Home (/user/myprofile)

Manage Accounts (/user/manage_accounts)

Change Password (/user/chgpwd)

Edit Profile (/user/edit)

Logout (/user/logout)

Submissions Menu

Submit Manuscript (/user/manuscripts/upload)

Display Submitted Manuscripts (/user/manuscripts/status)

Display Co-Authored Manuscripts (/user/manuscripts/co-authored)

English Editing (/user/pre_english_article/status)

Discount Vouchers (/user/discount_voucher)

Invoices (/user/invoices)

LaTex Word Count (/user/get/latex_word_count)

Journal: Pharmaceutics (https://www.mdpi.com/journal/pharmaceutics) (ISSN 1999-4923)

Manuscript ID: pharmaceutics-2071201

Type: Review

Title: Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review (https://www.mdpi.com/1999-4923/15/3/840)

Authors: Sri Hartati Yuliani * , Dina Christin Ayuning Putri , Dita Maria Virginia , Michael Raharja Gani , Florentinus Dika Octa Riswanto

Section: Physical Pharmacy and Formulation (https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation)

Special Issue: Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages (https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945)

Abstract: Extemporaneous preparations are still widely prescribed for pediatric patients or other patients requiring special treatments with certain doses and/or combinations of drugs. Several problems related to extemporaneous preparations have been linked to the incidence of adverse events. A review on the quality assessment of pharmaceutical compounding is presented. Several aspects related to evaluating the quality, including the stability and compatibility, of extemporaneous preparations are described and explained, following the investigation and collection of numerous scientific articles from reputable databases including Web of Science, Scopus, and PubMed. Compounded drugs are still needed by patients for medical reasons. However, it is important to ensure the quality of extemporaneous preparations in order to provide patient-oriented medication.

The coverletter for this review report has been saved in the database. You can safely close this window.

Authors' Responses to Reviewer's Comments (Reviewer 1)

Author's Notes: Thank you for the reviewers' valuable comments. We have read carefully all the comments and tried to make significant improvements to our paper. We changed the title of the manuscript

to “Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review”. We checked the structure and make a better connection between title, aim, methodology, and discussion. We focused our discussion on pediatric patients. Hence, we also highlight our main aim to provide patient-oriented compounding practice in developing nations. The amendments as well as the major corrections are highlighted in the manuscript with the green colored fonts.

Author's Notes File: Report Notes (/user/review/displayFile/33628479/r6yU9aXN?file=author-coverletter&report=25080331)

Review Report Form

Quality of English Language

( ) English very difficult to understand/incomprehensible
( ) Extensive editing of English language and style required
( ) Moderate English changes required
(x) English language and style are fine/minor spell check required
( ) I am not qualified to assess the quality of English in this paper

Is the work a significant contribution to the field?	★ ★ ★ ★ ★
Is the work well organized and comprehensively described?	★ ★ ★ ★ ★
Is the work scientifically sound and not misleading?	★ ★ ★ ★ ★
Are there appropriate and adequate references to related and previous work?	★ ★ ★ ★ ★
Is the English used correct and readable?	★ ★ ★ ★ ★

Comments and Suggestions for Authors

It appears that authors haven’t made any significant correction to previous version of the manuscript. Paper is still poorly structured in regard to its title and defined aim. Also, methodology is unacceptable.

The biggest part of this paper which should be a review of available literature concerning stability and compatibility in compounding for pediatric patients is written as a handbook. It seems that authors wish to show all relevant aspects for compounding of pediatric drugs whit the specific concern for the compounding process in developing countries. And we can read a paper with lot of facts substantiated by references. Yet, a topic – given by the title and the defined aim, and that is, a review on the quality assessment based on stability and compatibility of extemporaneous pediatric preparations is missing. The question of stability and compatibility is elaborated at one and a half page of the manuscript. And moreover that part is written more like

theoretical background regarding stability, without adequate experimental references related to the studies conducted in order to investigate stability.

This review is not in accordance to its title and defined aim. This paper looks like a review of challenges related to compounding pharmaceutical practice for pediatric patients in developing countries. And in this case authors should make necessary changes regarding the title and the aim of this paper. Still, even with a different title and aim, methodology in this paper is unsatisfactory.

Submission Date	17 November 2022
Date of this review	07 Dec 2022 13:49:54

User Menu

Home (/user/myprofile)

Manage Accounts (/user/manage_accounts)

Change Password (/user/chgpwd)

Edit Profile (/user/edit)

Logout (/user/logout)

Submissions Menu

Submit Manuscript (/user/manuscripts/upload)

Display Submitted Manuscripts (/user/manuscripts/status)

Display Co-Authored Manuscripts (/user/manuscripts/co-authored)

English Editing (/user/pre_english_article/status)

Discount Vouchers (/user/discount_voucher)

Invoices (/user/invoices)

LaTex Word Count (/user/get/latex_word_count)

Journal: Pharmaceutics (https://www.mdpi.com/journal/pharmaceutics) (ISSN 1999-4923)

Manuscript ID: pharmaceutics-2071201

Type: Review

Title: Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review (https://www.mdpi.com/1999-4923/15/3/840)

Authors: Sri Hartati Yuliani * , Dina Christin Ayuning Putri , Dita Maria Virginia , Michael Raharja Gani , Florentinus Dika Octa Riswanto

Section: Physical Pharmacy and Formulation (https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation)

Special Issue: Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages (https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945)

Abstract: Extemporaneous preparations are still widely prescribed for pediatric patients or other patients requiring special treatments with certain doses and/or combinations of drugs. Several problems related to extemporaneous preparations have been linked to the incidence of adverse events. A review on the quality assessment of pharmaceutical compounding is presented. Several aspects related to evaluating the quality, including the stability and compatibility, of extemporaneous preparations are described and explained, following the investigation and collection of numerous scientific articles from reputable databases including Web of Science, Scopus, and PubMed. Compounded drugs are still needed by patients for medical reasons. However, it is important to ensure the quality of extemporaneous preparations in order to provide patient-oriented medication.

The coverletter for this review report has been saved in the database. You can safely close this window.

Authors' Responses to Reviewer's Comments (Reviewer 1)

Author's Notes: **Title of Manuscript:**

Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review

General comments:

This is now very meaningful paper with research which answers the aim.

Response to Reviewer 1

We thank the reviewer for the comments. We also appreciate the reviewer for the positive effort to improve our manuscript's quality.

Author's Notes File: Report Notes (/user/review/displayFile/33628479/r6yU9aXN?file=author-coverletter&report=26524340)

Review Report Form

Quality of English Language
- ( ) English very difficult to understand/incomprehensible
- ( ) Extensive editing of English language and style required
- ( ) Moderate English changes required
- (x) English language and style are fine/minor spell check required
- ( ) I am not qualified to assess the quality of English in this paper

Is the work a significant contribution to the field?	★★★★★
Is the work well organized and comprehensively described?	★★★★★
Is the work scientifically sound and not misleading?	★★★★★
Are there appropriate and adequate references to related and previous work?	★★★★★
Is the English used correct and readable?	★★★★★

Comments and Suggestions for Authors: This is now very meaningful paper with research which answers the aim.

Submission Date: 17 November 2022

Date of this review: 20 Jan 2023 13:45:34

User Menu

Home (/user/myprofile)

Manage Accounts (/user/manage_accounts)

Change Password (/user/chgpwd)

Edit Profile (/user/edit)

Logout (/user/logout)

Submissions Menu

Submit Manuscript (/user/manuscripts/upload)

Display Submitted Manuscripts (/user/manuscripts/status)

Display Co-Authored Manuscripts (/user/manuscripts/co-authored)

English Editing (/user/pre_english_article/status)

Discount Vouchers (/user/discount_voucher)

Invoices (/user/invoices)

LaTex Word Count (/user/get/latex_word_count)

Journal: Pharmaceutics (https://www.mdpi.com/journal/pharmaceutics) (ISSN 1999-4923)

Manuscript ID: pharmaceutics-2071201

Type: Review

Title: Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review (https://www.mdpi.com/1999-4923/15/3/840)

Authors: Sri Hartati Yuliani * , Dina Christin Ayuning Putri , Dita Maria Virginia , Michael Raharja Gani , Florentinus Dika Octa Riswanto

Section: Physical Pharmacy and Formulation (https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation)

Special Issue: Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages (https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945)

Abstract: Extemporaneous preparations are still widely prescribed for pediatric patients or other patients requiring special treatments with certain doses and/or combinations of drugs. Several problems related to extemporaneous preparations have been linked to the incidence of adverse events. A review on the quality assessment of pharmaceutical compounding is presented. Several aspects related to evaluating the quality, including the stability and compatibility, of extemporaneous preparations are described and explained, following the investigation and collection of numerous scientific articles from reputable databases including Web of Science, Scopus, and PubMed. Compounded drugs are still needed by patients for medical reasons. However, it is important to ensure the quality of extemporaneous preparations in order to provide patient-oriented medication.

The coverletter for this review report has been saved in the database. You can safely close this window.

Authors' Responses to Reviewer's Comments (Reviewer 2)

Author's Notes: **Title of Manuscript:**

Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review

General comments:

Thanks much for taking into consideration the comments and rivising the manuscript. The revised version is much better. I would suggest discussing the paediatric focussed challenges related to stability and incompatibility related to quality assessment. Giving few pediatric specific examples might help.

Also, please note that the excipients are of concern and several factors needs to be taken into consideration such as route, dose, amount, diseases sverity, funactionality. Can you provide any specific examples where excipients have been used for extemp preparation and led to serious adverse effects?

Response to Reviewer 2

Thank you for the reviewers' valuable comments. We have revised the manuscript and made several improvements. The revised parts were highlighted in the manuscript with the green colored fonts.

The manuscript was revised as follows:

"Several literature review have summarized the safety and toxicity of pharmaceutical excipiets for pediatric patients. The health profesional should increase their awareness related to the risk of adverse event of exipients. Some exipients, such as arginin, aspartam, paraben, polyethyleneglycol, polysorbate, sorbitol, ethanol, etc., have reported giving adverse reaction. Parabens were the highest reported excipients and linked with several cases of adverse reactions in the pediatric population. Further, parabens were also associated with hypersensitivity reaction in pediatric, especially for neonatus. Other study was reported the risk of medication with sorbitol as exipient which has a potential negative effect such as diarrhea. Hence, it is important to consider the medication of pediatric and critically disease patients. The daily admissible intake of sorbitol according to European excipient review is limited to 5 mg/kg in children 0-2 years old, and 140 mg/kg in those older than 2 years." (Line 157-168)

Author's Notes File: Report Notes (/user/review/displayFile/33839704/febnET6U?file=author-coverletter&report=26524332)

Review Report Form

Quality of English:
( ) English very difficult to understand/incomprehensible
( ) Extensive editing of English language and style required

Language	( ) Moderate English changes required (x) English language and style are fine/minor spell check required ( ) I am not qualified to assess the quality of English in this paper

Is the work a significant contribution to the field?	★ ★ ★ ★ ★
Is the work well organized and comprehensively described?	★ ★ ★ ★ ★
Is the work scientifically sound and not misleading?	★ ★ ★ ★ ★
Are there appropriate and adequate references to related and previous work?	★ ★ ★ ★ ★
Is the English used correct and readable?	★ ★ ★ ★ ★

Comments and Suggestions for Authors	Thanks much for taking into consideration the comments and rivising the manuscript. The revised version is much better. I would suggest discussing the paediatric focussed challenges related to stability and incompatibility related to quality assessment. Giving few pediatric specific examples might help. Also, please note that the excipients are of concern and several factors needs to be taken into consideration such as route, dose, amount, diseases sverity, funactionality. Can you provide any specific examples where excipients have been used for extemp preparation and led to serious adverse effects?

Submission Date	17 November 2022
Date of this review	23 Jan 2023 15:55:24

User Menu

Home (/user/myprofile)

Manage Accounts (/user/manage_accounts)

Change Password (/user/chgpwd)

Edit Profile (/user/edit)

Logout (/user/logout)

Submissions Menu

Submit Manuscript (/user/manuscripts/upload)

Display Submitted Manuscripts (/user/manuscripts/status)

Display Co-Authored Manuscripts (/user/manuscripts/co-authored)

English Editing (/user/pre_english_article/status)

Discount Vouchers (/user/discount_voucher)

Invoices (/user/invoices)

LaTex Word Count (/user/get/latex_word_count)

Journal: Pharmaceutics (https://www.mdpi.com/journal/pharmaceutics) (ISSN 1999-4923)

Manuscript ID: pharmaceutics-2071201

Type: Review

Title: Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review (https://www.mdpi.com/1999-4923/15/3/840)

Authors: Sri Hartati Yuliani * , Dina Christin Ayuning Putri , Dita Maria Virginia , Michael Raharja Gani , Florentinus Dika Octa Riswanto

Section: Physical Pharmacy and Formulation (https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation)

Special Issue: Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages (https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945)

Abstract: Extemporaneous preparations are still widely prescribed for pediatric patients or other patients requiring special treatments with certain doses and/or combinations of drugs. Several problems related to extemporaneous preparations have been linked to the incidence of adverse events. A review on the quality assessment of pharmaceutical compounding is presented. Several aspects related to evaluating the quality, including the stability and compatibility, of extemporaneous preparations are described and explained, following the investigation and collection of numerous scientific articles from reputable databases including Web of Science, Scopus, and PubMed. Compounded drugs are still needed by patients for medical reasons. However, it is important to ensure the quality of extemporaneous preparations in order to provide patient-oriented medication.

The coverletter for this review report has been saved in the database. You can safely close this window.

Authors' Responses to Reviewer's Comments (Reviewer 2)

Author's Notes: Thank you for the reviewers' comments and suggestions which are a great value to improve our manuscript and guiding significantly our researches. We have carefully studied the comments and

made the significant revision which we hope to meet the approval. The amendments as well as the major corrections are highlighted in the manuscript and this rebuttal file with the green colored fonts.

==========

There are many other reasons why extemps are prepared for paeds and leads to adverse events such as medication preparation errors, dose accuracy, availability, affordability for LMICs, lack of appropriate formulation, different dosage forms, different age groups.

Response:

We have revised the manuscript as follow:

“The use of licensed drugs for pediatric patients has the potential to be dangerous, because excipients are not suitable for children, even if administered in small amounts. Since extemporaneous compounding was described as a branch of pharmacy practice to produce appropriate pharmaceutical preparations when there are no commercially available, licensed, and age-specific dosage forms, the problems related to stability, pharmacokinetic profile, and drug effect potentially occurred.”

We also added the statement as follow:

“Further, pharmacists require to control stability, compatibility, as well as provide formulation information to ensure patients were supplied with safe, high-quality, and effective preparations.”

Why was the keyword paediatrics not included?

Response:

We have added “pediatrics” as one of the keywords.

Spell the abbreviation when used for 1st time.

Response:

We have revised and added the abbreviation “International Monetary Fund (IMF)” in the manuscript.

It is bit offbeat. The article does not flow well. Some text are abruptly included. For example. In this case,theh prevalence in different countries is discussed and then drugs are listed. Is this country specific or common to all countries listed above?

Response:

We have revised the manuscript. We have removed the abrupt content and focused on the topics.

Thailand is excluded from table. Is there any particular reason?

Response:

We have added a study from Thailand.

It is highlighted several places in the article that it is important to ensure quality, however, the reasons for doing so is missing. Also examples are missing to highlight the impact. Did you come across any references where assessing the quality has resulted in positive outcome while not doing so as resulted in negative outcome?

Response:

We have revised the manuscript. The importance to ensure quality of extemporaneous preparation was to provide patient-oriented medication. This statement was added in abstract section to strengthen the aim of the paper. We did not come across any references.

As mentioned earlier, it abruptly moves to different routes. It might be helpful to consolidate common areas/themes for discussion.

Response:

We have carefully evaluated the usage of gentamicin and hydrocortisone for pediatrics patient, especially for the treatment of scabies.

Is this pediatric product???

Response:

Thank you for the comments. We have removed inappropriate citations to the topics.

The section states general issues .. nothing specific to paediatric population.

Response:

We have revised the manuscript and focused on pediatric population.

I belive inappropriate reference is stated and discussed here. There are many references where excipients such as suspending agents are used for extemporaneous and has led to side effects. Such references should be discussed. The scope of teh article is not to discusses issues of excipients of excipients in general but to

to discuss issues of excipients related to compounding. Clinicians/pharmacists struggle to find appropriate safety information to make informed decision on selection of excipients for compounding such issues should be discussed in this paper

Response:

Thank you for the suggestion. We have removed inappropriate references and kept the supported references. The safety information related to the excipient of concern were discussed in the section of the challenges of compounding practices.

I would restrain from using the word 'harmful' as it depends on the several factors, age group, route, etc. which are not discussed in this paper. Inlcusion of the excipients in the product does not necessarily mean they are harmful, you need to assess the doe, amount, route of administration, severity of diseases, dosage form, age group. etc. You can call them excipients of concern but not declare them harmful.

Response:

We have revised the manuscript and changed the phrase ‘harmful’ into ‘excipients of concern’.

Do you intend to focus the paper on developing countries?? then it would be good to reflect that in title. Also, please refer to terminology of developing countries. Today, the preferred terminology is a **developing nation**, an underdeveloped country, or a low- and middle-income country (LMIC).

Response:

We have changed the terminology of developing countries into developing nations.

This table is not needed or needs to be replaced with information specific to compounding effects of excipients? This is not new and has been included several times in the literature so appropriate references summary the adv effects of excipients can be included instead of table.

Response:

We kept providing the table since Table 2 presented a summary or list regarding excipients of concern for children.

are these for paediatric population?

Response:

According to the cited article, it was reported that ambroxol hydrochloride and salbutamol sulfate were prescribed for pediatrics in our previous study.

again what is relevance to paediatric?

Response:

According to the cited article, it was reported that acetylsalicylic acid was prescribed for pediatrics in Brazil as a developing nation. However, the usage of acetylsalicylic acid should be evaluated further according to the toxicity report of acetylsalicylic acid for pediatrics medication.

no mention of paediatric?

Response:

In the section of “Lack of regulatory guidance” we have mentioned pediatrics limitedly. However, it is common knowledge that regulations covered several aspects of medication in different ages. We also mentioned a case of children’s death related to compounding failure.

Overall, the article is not well articulated. Several elements are missing. the quality assessment aspects is very vaguely discussed. It more highlights the issues with compounded preparation but again very abruptly. This is an important area which needs attention for betterment of children

Response:

We have revised the structure of manuscript. We also change the title of the manuscript in order improve the relevance between title and the whole manuscript. We also strengthen the manuscript by focusing the discussion on pediatric patients.

Author's Notes File: Report Notes (/user/review/displayFile/33839704/febnET6U?file=author-coverletter&report=25247277)

Review Report Form

Quality of English Language

( ) English very difficult to understand/incomprehensible
( ) Extensive editing of English language and style required
(x) Moderate English changes required
( ) English language and style are fine/minor spell check required
( ) I am not qualified to assess the quality of English in this paper

Is the work a significant contribution to the field? ★ ★ ★ ★ ★

Is the work well organized and comprehensively described?	★ ★ ★ ★ ★
Is the work scientifically sound and not misleading?	★ ★ ★ ★ ★
Are there appropriate and adequate references to related and previous work?	★ ★ ★ ★ ★
Is the English used correct and readable?	★ ★ ★ ★ ★

Comments and Suggestions for Authors

This article provides a review on the quality assessment of pharmaceutical compunding products. It covers few important aspects, however, they are very vaguely discussed and very limited references are included. The inroduction is very weak and does not clealry explain the rationale of the paper. I woudl help to give some examples on how quality has impaired the health of ped populations or impact of quality on health of pediatric population. The article does not match the title. Title mentions paediatric, however introduction does not focus on paediatrics and neither the aims and objectives. Does that article aim to highlight the need of quality assessment of extemp preparations or does it aim to include the different methods of quality assessments. It is very vague and does not clearly focus on one or other aspects. The aim suggests that the authors provides the review on several aspects but then it needs to summarise a short section on what aspects it covers as there are many other aspects that are not even listed in the paper. Hence the research work on this topic seems to be very limited for a review.

The attached pdf provides further detailed comments. I hope you find them helpful for the revision of the article. All the best!

peer-review-25247277.v2.pdf (/user/review/displayFile/33839704/febnET6U?file=review&report=25247277)

Submission Date	17 November 2022
Date of this review	20 Dec 2022 11:32:02

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Revision Update

marta.spasic@mdpi.com <marta.spasic@mdpi.com>
atas nama
Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Sen 09/01/2023 14.12

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Dear Dr. Yuliani,

We sent a revision request for the following manuscript on 20 December 2022.

Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Stability and Compatibility Approach for Quality Assessment of Pharmaceutical Compounding for Pediatric Patients
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945

May we kindly ask you to update us on the progress of your revisions? If you have finished your revisions, please upload the revised version together with your responses to the reviewers as soon as possible.

You can find your manuscript and review reports at this link:
https://susy.mdpi.com/user/manuscripts/resubmit/f556c3b2fd38fcb291a9e88e9e45bdd9

Thank you in advance for your kind cooperation and we look forward to hearing from you soon.

Kind regards,
Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma

LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:
https://www.mdpi.com/about/announcements/4307

Awards Open for Application:
https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 7455 363

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Revision Reminder

marta.spasic@mdpi.com <marta.spasic@mdpi.com>
atas nama
Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Kam 12/01/2023 15.36

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Dear Dr. Yuliani,

We sent a revision request for the following manuscript on 20 December 2022.

Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Stability and Compatibility Approach for Quality Assessment of Pharmaceutical Compounding for Pediatric Patients
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945

May we kindly ask you to update us on the progress of your revisions? If you have finished your revisions, please upload the revised version together with your responses to the reviewers as soon as possible.

You can find your manuscript and review reports at this link:
https://susy.mdpi.com/user/manuscripts/resubmit/f556c3b2fd38fcb291a9e88e9e45bdd9

Thank you in advance for your kind cooperation and we look forward to hearing from you soon.

Kind regards,
Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma

LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:
https://www.mdpi.com/about/announcements/4307

Awards Open for Application:
https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 7455 363

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Manuscript Resubmitted

susy@mdpi.com <susy@mdpi.com>
atas nama
Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Jum 13/01/2023 17.10

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>

Dear Dr. Yuliani,

Thank you very much for resubmitting the modified version of the following manuscript:

Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Stability and Compatibility Approach for Quality Assessment of Pharmaceutical Compounding for Pediatric Patients
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945
https://susy.mdpi.com/user/manuscripts/review_info/f556c3b2fd38fcb291a9e88e9e45bdd9

A member of the editorial office will be in touch with you soon regarding progress of the manuscript.

Kind regards,
Pharmaceutics Editorial Office
Postfach, CH-4020 Basel, Switzerland
Office: St. Alban-Anlage 66, CH-4052 Basel
Tel. +41 61 683 77 34 (office)
E-mail: pharmaceutics@mdpi.com
https://www.mdpi.com/journal/pharmaceutics/

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Revised Version Received

marta.spasic@mdpi.com <marta.spasic@mdpi.com>
atas nama
Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Rab 25/01/2023 17.00

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Dear Dr. Yuliani,

Thank you very much for providing the revised version of your paper:

Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945
https://susy.mdpi.com/user/manuscripts/review_info/f556c3b2fd38fcb291a9e88e9e45bdd9

We will continue processing your paper and will keep you informed about the status of your submission.

Kind regards,
Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma
LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:
https://www.mdpi.com/about/announcements/4307

Awards Open for Application:

https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 414 75 49

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Minor Revisions

marta.spasic@mdpi.com <marta.spasic@mdpi.com>
atas nama
Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Kam 26/01/2023 21.07

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Dear Dr. Yuliani,

Thank you again for your manuscript submission.

Our Academic Editor provided comments about additional issues that should be addressd. Please find your manuscript with the referee reports and Editor's comments at this link:
https://susy.mdpi.com/user/manuscripts/resubmit/f556c3b2fd38fcb291a9e88e9e45bdd9

(I) Please revise your manuscript according to the comments and upload the revised file within 1 day.
(II) Please use the version of your manuscript found at the above link for your revisions.
(III) Please check that all references are relevant to the contents of the manuscript.
(IV) Any revisions made to the manuscript should be marked up using the "Track Changes" function if you are using MS Word/LaTeX, such that changes can be easily viewed by the editors and reviewers.
(V) Please provide a short cover letter detailing your changes for the editors' approval.

If one of the referees has suggested that your manuscript should undergo extensive English revisions, please address this issue during revision. We propose that you use one of the editing services listed at https://www.mdpi.com/authors/english or have your manuscript checked by a native English-speaking colleague.

Please do not hesitate to contact us if you have any questions regarding the revision of your manuscript or if you need more time. We look forward to hearing from you soon.

Kind regards,
Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma
LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:
https://www.mdpi.com/about/announcements/4307

Awards Open for Application:
https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 414 75 49

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Revised Version Received

marta.spasic@mdpi.com <marta.spasic@mdpi.com>
atas nama
Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Jum 27/01/2023 16.45

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Dear Dr. Yuliani,

Thank you very much for providing the revised version of your paper:

Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945
https://susy.mdpi.com/user/manuscripts/review_info/f556c3b2fd38fcb291a9e88e9e45bdd9

We will continue processing your paper and will keep you informed about the status of your submission.

Kind regards,
Ms. Marta Spasic
Assistant Editor, MDPI Belgrade
E-Mail: marta.spasic@mdpi.com

Pharmaceutics
(http://www.mdpi.com/journal/pharmaceutics)
Twitter: https://twitter.com/MDPIpharma
LinkedIn: https://www.linkedin.com/company/pharmaceutics-mdpi/

Pharmaceutics - Special Issue Mentor Program:
https://www.mdpi.com/about/announcements/4307

Awards Open for Application:

https://www.mdpi.com/journal/pharmaceutics/awards

MDPI Branch Office, Belgrade
Bulevar Milutina Milankovica 7v, 11070 Belgrade, Serbia
+381 11 414 75 49

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Funding Information Confirmation

marta.spasic@mdpi.com <marta.spasic@mdpi.com>
atas nama
Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Sel 07/02/2023 19.40

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>;Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>

Cc: Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>;Marta Spasic <marta.spasic@mdpi.com>

Dear Authors,

When you submitted, you added the following funding information in the system. Your manuscript has now been accepted. Please carefully check and ensure that the funding information is correct in any places where it appears in your manuscript.

Funding information in our system:
Ministry of Education and Culture: Grant number 157/E5/PG.02.00.PT/2022; No 1989.9/LL5-INT/PG.02.00/2022; and 028/Penel./LPPM-USD/V/2022

Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945

You can check it at:
https://susy.mdpi.com/user/manuscripts/review_info/f556c3b2fd38fcb291a9e88e9e45bdd9

If you have any questions or if you require any modifications, please contact us.

Kind regards,
Submission System

Set Up Your Profile at SciProfiles.com

Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

Sel 07/02/2023 19.40

Kepada: Michael Raharja Gani <mr_gani@usd.ac.id>

Cc: Marta Spasic <marta.spasic@mdpi.com>

Dear Mr. Gani,

Congratulations on your paper being accepted for publication in Pharmaceutics.

To enhance your visibility, as well as that of your co-authors, we would like to invite you to set up profiles on SciProfiles (https://sciprofiles.com). Once you have finished the registration process, we will update mdpi.com to link all your articles to your profile.

You can use the link below to register or log in using your MDPI credentials:
https://sciprofiles.com/author_registration/f556c3b2fd38fcb291a9e88e9e45bdd9/Y085WXR1NGM1dld0MDQwK0VMcVlsUTlaUlB5ZUdacWpMK0JPSzd3eEZqND0=

When filling in your profile, please:
1. Use the email address that is associated with your publications if possible;
2. Add a photo to help colleagues to identify you easily and to enhance the visibility of your profile;
3. Verify your ORCID ID so that publication records from your ORCID can then be added to your profile automatically;
4. Populate your profile with any projects, past and current, or conferences you have attended or plan to attend.

If you have any questions, please feel free to visit the FAQs page (https://sciprofiles.com/help-center) or contact us at info@sciprofiles.com or via the contact form here (https://sciprofiles.com/contact).

Kind regards,

Dr. Shu-Kun Lin and the SciProfiles Team

Re: [Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Final Proofreading Before Publication

Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Jum 10/02/2023 19.15

Kepada: Marta Spasic <marta.spasic@mdpi.com>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>;sunny.xu@mdpi.com <sunny.xu@mdpi.com>;Marta Spasic <marta.spasic@mdpi.com>

Dear Marta,

Thank you for the proofreading version. We affraid we can not complete the task during 24 hours due to several weekend activities and office job on Monday and Tuesday. We are hoping the Editor to provide longer time to finish this task. We plan to submit the final proofreading file on Wednesday. Thank you in advance.

Regards,
Dr. Sri Hartati Yuliani

Get Outlook for Android

From: sunny.xu@mdpi.com <sunny.xu@mdpi.com> on behalf of Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>
Sent: Friday, February 10, 2023 9:43:24 AM
To: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>
Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>; Dita Maria Virginia <virginia@usd.ac.id>; Michael Raharja Gani <mr_gani@usd.ac.id>; Dika Octa <dikaocta@usd.ac.id>; Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>; sunny.xu@mdpi.com <sunny.xu@mdpi.com>; Marta Spasic <marta.spasic@mdpi.com>
Subject: [Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Final Proofreading Before Publication

Dear Dr. Yuliani,

We invite you to proofread your manuscript to ensure that this is the final version that can be published and confirm that you will require no further changes:

At MDPI, we believe in the fast dissemination of sound, valid scientific knowledge. Once accepted for publication, we aim to ensure that research is published as soon as possible.

Please upload the final proofread version of your manuscript within 24 hours, and please remember that we are able to be flexible with this timeframe should you alert us. If you need more time, please inform the Assistant Editor of the expected date that you will be able to return the proofread version.

Manuscript ID: pharmaceutics-2071201
Type of manuscript: Review
Title: Prevalence, risk, and challenges of extemporaneous preparation for pediatric patients in developing nations: A review
Authors: Sri Hartati Yuliani *, Dina Christin Ayuning Putri, Dita Maria Virginia, Michael Raharja Gani, Florentinus Dika Octa Riswanto
Received: 17 November 2022
E-mails: srihartatiyuliani@usd.ac.id, dinachristin@usd.ac.id, virginia@usd.ac.id, mr_gani@usd.ac.id, dikaocta@usd.ac.id
Submitted to section: Physical Pharmacy and Formulation, https://www.mdpi.com/journal/pharmaceutics/sections/Physical_Pharmacy_Formulation
Pharmacy Compounding of Personalized Preparation for Specific Patients: Challenges and Advantages
https://www.mdpi.com/journal/pharmaceutics/special_issues/0LMCZPN945

Please read the following instructions carefully before proofreading:

1) Download the manuscript from the link provided at the end of this message and upload the final proofed version via the second link. If you experience any difficulties, please contact the Pharmaceutics Editorial Office.

2) Please use Microsoft Word's built-in track changes function to highlight any changes you make, or send a comprehensive list of changes in a separate document. Note that this is the *last chance* to make textual changes to the manuscript. Some style and formatting changes may have been made by the production team, please do not revert these changes.

3) All authors must agree to the final version. Check carefully that authors' names and affiliations are correct, and that funding sources are correctly acknowledged. Incorrect author names or affiliations are picked up by indexing databases, such as the Web of Science or PubMed, and can be difficult to correct.

After proofreading, final production will be carried out. Note that changes to the position of figures and tables may occur during the final steps. Changes can be made to a paper published online only at the discretion of the Editorial Office.

Please download the final version of your paper for proofreading here:

https://susy.mdpi.com/user/manuscripts/proof/file/f556c3b2fd38fcb291a9e88e9e45bdd9

and upload here:

https://susy.mdpi.com/user/manuscripts/resubmit/f556c3b2fd38fcb291a9e88e9e45bdd9

This manuscript includes supplementary materials, which you can find at the

second link, above. Please note that citations and references in Supplementary files are permitted provided that they also appear in the reference list of the main text. Please ensure that you proofread your supplementary materials and upload them together with the manuscript.

We look forward to hearing from you soon.

Kind regards,
Ms. Sunny Xu
Production Editor
E-Mail: sunny.xu@mdpi.com

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Payment Reminder - Invoice ID: pharmaceutics-2071201

MDPI Billing <billing@mdpi.com>

Jum 24/02/2023 21.53

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>;Marta Spasic <marta.spasic@mdpi.com>;Billing Dept <billing@mdpi.com>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

1 lampiran (31 KB)

Invoice_MDPI_pharmaceutics-2071201_2040.00CHF.pdf;

Dear Dr. Yuliani,

This is a gentle reminder that we have not received the payment for the invoice sent on 7 February 2023, see details below. Please let us know if you have encountered difficulties regarding the payment procedure so that we may assist you. We understand sometimes the payment may be delayed due to specific university procedures, and kindly ask you to keep us updated.

Invoice ID: pharmaceutics-2071201
Invoice Amount: 2040.00 CHF
Invoice date: 7 February 2023

Follow this link to adjust the currency, change the address, or add comments, as necessary:
https://susy.mdpi.com/user/manuscript/f556c3b2fd38fcb291a9e88e9e45bdd9/invoice/2009379

For immediate payment by credit card, visit https://payment.mdpi.com/2009379.

If you would like to use a different method of payment, click here: https://www.mdpi.com/about/payment. Please include the invoice ID (pharmaceutics-2071201) as reference in any transaction.

Should you have any question regarding the payment process, please contact our billing staff by e-mail at invoices@mdpi.com. Additionally, please visit our FAQ page: https://www.mdpi.com/about/apc_faq}.

Only official emails sent by MDPI (@mdpi.com) are valid. Please check that the sender's email is affiliated with @mdpi.com. We do not authorize any third party to provide email services. MDPI is the sole service provider, and therefore cannot be held liable for actions performed by any third party.

If your payment has already been sent, please disregard this message.

Kind regards,

MDPI Billing Team

MDPI
St. Alban-Anlage 66
4052 Basel, Switzerland
Tel. +41 61 683 77 35; Fax +41 61 302 89 18
E-mail Accounting: billing@mdpi.com
http://www.mdpi.com/
https://www.mdpi.com/about/apc_faq

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201 - Payment Confirmation pharmaceutics-2071201

MDPI Billing <billing@mdpi.com>

Sab 25/02/2023 18.45

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>

Cc: Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>;Marta Spasic <marta.spasic@mdpi.com>;MDPI Billing <billing@mdpi.com>;Pharmaceutics Editorial Office <pharmaceutics@mdpi.com>

1 lampiran (25 KB)

receipt_MDPI_pharmaceutics-2071201.pdf;

Dear Dr. Yuliani,

Many thanks for your support of open access publishing. Please find below the APC payment confirmation for the following article:

Payment of Invoice: pharmaceutics-2071201
Amount Received: 2040.00 CHF
Date Received: 25 February 2023

Payer Information

Sri Hartati Yuliani
Universitas Sanata Dharma
Kampus III Universitas Sanata Dharma Paingan Maguwohardjo Depok Sleman Yogyakarta Indonesia
55282 Sleman
Indonesia

For your convenience, we attach the payment confirmation as PDF.

Please feel free to contact us in case of questions.

Kind regards,
MDPI Billing Team

MDPI
St. Alban-Anlage 66
4052 Basel, Switzerland
Tel. +41 61 683 77 35; Fax +41 61 302 89 18

E-mail Accounting: billing@mdpi.com
http://www.mdpi.com/
https://www.mdpi.com/about/apc_faq

[Pharmaceutics] Manuscript ID: pharmaceutics-2071201; doi: 10.3390/pharmaceutics15030840. – Promotion Tips

ting.jie@mdpi.com <ting.jie@mdpi.com>
atas nama
pharmaceutics@mdpi.com <pharmaceutics@mdpi.com>
Sab 04/03/2023 09.16

Kepada: Sri Hartati Yuliani <srihartatiyuliani@usd.ac.id>;Dina Christin Ayuning Putri <dinachristin@usd.ac.id>;Dita Maria Virginia <virginia@usd.ac.id>;Michael Raharja Gani <mr_gani@usd.ac.id>;Dika Octa <dikaocta@usd.ac.id>

Cc: pharmaceutics@mdpi.com <pharmaceutics@mdpi.com>;marta.spasic@mdpi.com <marta.spasic@mdpi.com>

Dear Authors,

Congratulations! Your manuscript has been published open access in Pharmaceutics.

Thank you for choosing our journal. Your article is now publicly and freely available on the journal website. As part of the post-publication process, we encourage you to promote and share your work to increase its visibility, impact, and citations.

Please find the Publication Certificate and a banner for promoting your manuscript here (please note, this is only available to corresponding authors when logged into their account):
https://susy.mdpi.com/user/manuscripts/review_info/f556c3b2fd38fcb291a9e88e9e45bdd9

To promote the discoverability, views, and downloads of your manuscript you can promote your manuscript in the following ways:

(1) Social Media
- Share your article on various social networks, such as Researchgate, Sciprofiles Facebook, LinkedIn, Mendeley, and Twitter by clicking the share button on the webpage of your article. Please do not forget to tag us, @MDPIOpenAccess so that we can re-tweet your work to further increase its visibility.
- Send a short text (up to 200 characters) to the MDPI assistant editor who was your contact for the publication of your manuscript to post about your manuscript on the journal's Twitter account.
- Write a blog post to explain the meaning and possible outcomes of your Research.
- Ask your institution or society to post your paper on their social media accounts and to include a story about your paper in their newsletters.

(2) Link Share
- Share the article link directly with colleagues and peers in your field.
- Add a link to your article in your email signature.

- Update your personal and institutional websites by adding the title of your article and a link to it.

(3) Academic Research-sharing Platforms
- Set up your profile on academic research-sharing platforms, such as SciProfiles, ResearchGate, Academia.edu, or Google Scholar, and add a summary of your article.
- Register an ORCID author identifier and add the article information to your profile.
- Deposit your article in repositories (such as those run by your university) to make your research more discoverable.

(4) Conferences
- Showcase your publication at conferences in the form of a presentation or a poster. You can find conferences hosted by MDPI to participate in at Sciforum.net.

For additional tips to promote your article please see here:
https://www.mdpi.com/authors/promoting

Please keep up with any journal updates and news via our twitter account (https://twitter.com/MDPIpharma)or LinkedIn page (https://www.linkedin.com/company/pharmaceutics-mdpi/?viewAsMember=true).
Find out more about MDPI on our website: https://www.mdpi.com/about.

Please keep in touch!

Kind regards,
Pharmaceutics Editorial Office
St. Alban-Anlage 66, 4052 Basel, Postfach, CH-4020 Basel, Switzerland
Tel.: +41 61 683 77 34;
E-Mail: pharmaceutics@mdpi.com
https://www.mdpi.com/journal/pharmaceutics
